Short Interest in Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Expands By 263.6%

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) saw a large increase in short interest in April. As of April 15th, there was short interest totalling 36,000 shares, an increase of 263.6% from the March 31st total of 9,900 shares. Approximately 0.5% of the shares of the stock are sold short. Based on an average daily volume of 154,900 shares, the days-to-cover ratio is currently 0.2 days.

Sol-Gel Technologies Price Performance

Shares of SLGL stock traded up $0.01 on Tuesday, hitting $0.83. 31,783 shares of the company’s stock were exchanged, compared to its average volume of 280,708. Sol-Gel Technologies has a 12 month low of $0.33 and a 12 month high of $1.65. The stock has a market cap of $22.98 million, a P/E ratio of -2.43 and a beta of 1.24. The company has a 50 day moving average of $0.56 and a 200 day moving average of $0.67.

Institutional Trading of Sol-Gel Technologies

A hedge fund recently bought a new stake in Sol-Gel Technologies stock. Raymond James Financial Inc. bought a new stake in Sol-Gel Technologies Ltd. (NASDAQ:SLGL) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 108,990 shares of the company’s stock, valued at approximately $101,000. Raymond James Financial Inc. owned about 0.39% of Sol-Gel Technologies at the end of the most recent quarter. Hedge funds and other institutional investors own 26.18% of the company’s stock.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.